These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

195 related items for PubMed ID: 7855196

  • 1. Effects of typical and atypical antipsychotic drugs on two-way active avoidance. Relationship to DA receptor blocking profile.
    Ogren SO, Archer T.
    Psychopharmacology (Berl); 1994 Apr; 114(3):383-91. PubMed ID: 7855196
    [Abstract] [Full Text] [Related]

  • 2. Neuropsychopharmacological profile of remoxipride in comparison with clozapine.
    Skuza G, Rogóz Z, Wieczorek A.
    Pol J Pharmacol; 1997 Apr; 49(1):5-15. PubMed ID: 9431546
    [Abstract] [Full Text] [Related]

  • 3. Effects of remoxipride's metabolites on dopamine D2 receptors and receptor functions in the rat.
    Ogren SO, Hall H, Widman M, Angeby-Möller K.
    Pharmacol Toxicol; 1993 Dec; 73(6):325-34. PubMed ID: 8153056
    [Abstract] [Full Text] [Related]

  • 4. Remoxipride, a new potential antipsychotic compound with selective antidopaminergic actions in the rat brain.
    Ogren SO, Hall H, Köhler C, Magnusson O, Lindbom LO, Angeby K, Florvall L.
    Eur J Pharmacol; 1984 Jul 20; 102(3-4):459-74. PubMed ID: 6149133
    [Abstract] [Full Text] [Related]

  • 5. Effects of buspirone on dopamine dependent behaviours in rats.
    Dhavalshankh AG, Jadhav SA, Gaikwad RV, Gaonkar RK, Thorat VM, Balsara JJ.
    Indian J Physiol Pharmacol; 2007 Jul 20; 51(4):375-86. PubMed ID: 18476392
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. WAY-163909, a 5-HT2C agonist, enhances the preclinical potency of current antipsychotics.
    Grauer SM, Graf R, Navarra R, Sung A, Logue SF, Stack G, Huselton C, Liu Z, Comery TA, Marquis KL, Rosenzweig-Lipson S.
    Psychopharmacology (Berl); 2009 May 20; 204(1):37-48. PubMed ID: 19107466
    [Abstract] [Full Text] [Related]

  • 8. D1 and D2 dopamine receptor-mediated mechanisms and behavioral supersensitivity.
    Marin C, Parashos SA, Kapitzoglou-Logothetis V, Peppe A, Chase TN.
    Pharmacol Biochem Behav; 1993 May 20; 45(1):195-200. PubMed ID: 8516358
    [Abstract] [Full Text] [Related]

  • 9. [Selective antidopaminergic properties of remoxiprid, a new potential antipsychotic agent].
    Ogren SO, Hall H, Köhler C, Magnusson O, Florvall L.
    Arzneimittelforschung; 1985 May 20; 35(8):1227-31. PubMed ID: 2866774
    [Abstract] [Full Text] [Related]

  • 10. WAY-163909 [(7bR,10aR)-1,2,3,4,8,9,10,10a-octahydro-7bH-cyclopenta-[b][1,4]diazepino[6,7,1hi]indole]: A novel 5-hydroxytryptamine 2C receptor-selective agonist with preclinical antipsychotic-like activity.
    Marquis KL, Sabb AL, Logue SF, Brennan JA, Piesla MJ, Comery TA, Grauer SM, Ashby CR, Nguyen HQ, Dawson LA, Barrett JE, Stack G, Meltzer HY, Harrison BL, Rosenzweig-Lipson S.
    J Pharmacol Exp Ther; 2007 Jan 20; 320(1):486-96. PubMed ID: 17038512
    [Abstract] [Full Text] [Related]

  • 11. Dissociation between in vivo occupancy and functional antagonism of dopamine D2 receptors: comparing aripiprazole to other antipsychotics in animal models.
    Natesan S, Reckless GE, Nobrega JN, Fletcher PJ, Kapur S.
    Neuropsychopharmacology; 2006 Sep 20; 31(9):1854-63. PubMed ID: 16319908
    [Abstract] [Full Text] [Related]

  • 12. Psychopharmacological profile of amisulpride: an antipsychotic drug with presynaptic D2/D3 dopamine receptor antagonist activity and limbic selectivity.
    Perrault G, Depoortere R, Morel E, Sanger DJ, Scatton B.
    J Pharmacol Exp Ther; 1997 Jan 20; 280(1):73-82. PubMed ID: 8996184
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Enhanced efficacy of both typical and atypical antipsychotic drugs by adjunctive alpha2 adrenoceptor blockade: experimental evidence.
    Wadenberg ML, Wiker C, Svensson TH.
    Int J Neuropsychopharmacol; 2007 Apr 20; 10(2):191-202. PubMed ID: 16707032
    [Abstract] [Full Text] [Related]

  • 15. Antagonism at 5-HT(2A) receptors potentiates the effect of haloperidol in a conditioned avoidance response task in rats.
    Wadenberg MG, Browning JL, Young KA, Hicks PB.
    Pharmacol Biochem Behav; 2001 Mar 20; 68(3):363-70. PubMed ID: 11325387
    [Abstract] [Full Text] [Related]

  • 16. The NMDA positive modulator D-cycloserine potentiates the neuroleptic activity of D1 and D2 dopamine receptor blockers in the rat.
    Dall'Olio R, Gandolfi O.
    Psychopharmacology (Berl); 1993 Mar 20; 110(1-2):165-8. PubMed ID: 7870878
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Different inhibition of conditioned avoidance response by clozapine and DA D1 and D2 antagonists in male mice.
    Aguilar MA, Marí-Sanmillán MI, Morant-Deusa JJ, Miñarro J.
    Behav Neurosci; 2000 Apr 20; 114(2):389-400. PubMed ID: 10832799
    [Abstract] [Full Text] [Related]

  • 19. Pharmacological profile of SCH39166: a dopamine D1 selective benzonaphthazepine with potential antipsychotic activity.
    Chipkin RE, Iorio LC, Coffin VL, McQuade RD, Berger JG, Barnett A.
    J Pharmacol Exp Ther; 1988 Dec 20; 247(3):1093-102. PubMed ID: 2905002
    [Abstract] [Full Text] [Related]

  • 20. Hypotensive and bradycardic effects elicited by spinal dopamine receptor stimulation: effects of D1 and D2 receptor agonists and antagonists.
    Pellissier G, Demenge P.
    J Cardiovasc Pharmacol; 1991 Oct 20; 18(4):548-55. PubMed ID: 1724532
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.